These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34261294)

  • 21. How do we manage t(11;14) plasma cell disorders with venetoclax?
    Chakraborty R; Bhutani D; Lentzsch S
    Br J Haematol; 2022 Oct; 199(1):31-39. PubMed ID: 35594184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secondary plasma cell leukaemia treated with single agent venetoclax.
    Glavey SV; Flanagan L; Bleach R; Kelly C; Quinn J; Ní Chonghaile T; Murphy P
    Br J Haematol; 2020 Aug; 190(4):e242-e245. PubMed ID: 32525557
    [No Abstract]   [Full Text] [Related]  

  • 23. Venetoclax in myeloma: to B, or not to B.
    Raab MS
    Blood; 2024 Jan; 143(1):4-5. PubMed ID: 38175678
    [No Abstract]   [Full Text] [Related]  

  • 24. Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency.
    Leblay N; Ahn S; Tilmont R; Poorebrahim M; Maity R; Lee H; Barakat E; Alberge JB; Sinha S; Jaffer A; Barwick BG; Boise LH; Bahlis N; Neri P
    Blood; 2024 Jan; 143(1):42-56. PubMed ID: 37729611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCL2 blockade overcomes MCL1 resistance in multiple myeloma.
    Siu KT; Huang C; Panaroni C; Mukaihara K; Fulzele K; Soucy R; Thorburn C; Cidado J; Drew L; Chattopadhyay S; Raje N
    Leukemia; 2019 Aug; 33(8):2098-2102. PubMed ID: 30816329
    [No Abstract]   [Full Text] [Related]  

  • 26. Waldenstrom macroglobulinemia cells devoid of BTK
    Paulus A; Akhtar S; Yousaf H; Manna A; Paulus SM; Bashir Y; Caulfield TR; Kuranz-Blake M; Chitta K; Wang X; Asmann Y; Hudec R; Springer W; Ailawadhi S; Chanan-Khan A
    Blood Cancer J; 2017 May; 7(5):e565. PubMed ID: 28548645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.
    Matulis SM; Gupta VA; Neri P; Bahlis NJ; Maciag P; Leverson JD; Heffner LT; Lonial S; Nooka AK; Kaufman JL; Boise LH
    Leukemia; 2019 May; 33(5):1291-1296. PubMed ID: 30679802
    [No Abstract]   [Full Text] [Related]  

  • 28. Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma.
    Boccon-Gibod C; Talbot A; Le Bras F; Frenzel L; Royer B; Harel S; Lombion N; Belhadj K; Cuccuini W; Arnulf B
    Br J Haematol; 2020 May; 189(3):e73-e76. PubMed ID: 32012229
    [No Abstract]   [Full Text] [Related]  

  • 29. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics.
    Touzeau C; Ryan J; Guerriero J; Moreau P; Chonghaile TN; Le Gouill S; Richardson P; Anderson K; Amiot M; Letai A
    Leukemia; 2016 Mar; 30(3):761-4. PubMed ID: 26174630
    [No Abstract]   [Full Text] [Related]  

  • 30. Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma.
    Sharma A; Nair R; Achreja A; Mittal A; Gupta P; Balakrishnan K; Edgar CL; Animasahun O; Dwivedi B; Barwick BG; Gupta VA; Matulis SM; Bhasin M; Lonial S; Nooka AK; Wiita AP; Boise LH; Nagrath D; Shanmugam M
    Sci Adv; 2022 Sep; 8(39):eabq5575. PubMed ID: 36170375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paving the way to precision medicine in multiple myeloma.
    Inam S; Ross JA; Touzeau C; Moreau P; Kumar SK; Harrison SJ
    Expert Rev Hematol; 2021 Apr; 14(4):323-327. PubMed ID: 33729865
    [No Abstract]   [Full Text] [Related]  

  • 32. Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML.
    Karjalainen R; Liu M; Kumar A; He L; Malani D; Parsons A; Kontro M; Kallioniemi O; Porkka K; Heckman CA
    Leukemia; 2019 Oct; 33(10):2548-2553. PubMed ID: 31175323
    [No Abstract]   [Full Text] [Related]  

  • 33. Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression.
    Lochmann TL; Floros KV; Naseri M; Powell KM; Cook W; March RJ; Stein GT; Greninger P; Maves YK; Saunders LR; Dylla SJ; Costa C; Boikos SA; Leverson JD; Souers AJ; Krystal GW; Harada H; Benes CH; Faber AC
    Clin Cancer Res; 2018 Jan; 24(2):360-369. PubMed ID: 29118061
    [No Abstract]   [Full Text] [Related]  

  • 34. Prospects for Venetoclax in Myelodysplastic Syndromes.
    Garcia JS
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):441-448. PubMed ID: 32089221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.
    Seymour J
    Clin Adv Hematol Oncol; 2019 Aug; 17(8):440-443. PubMed ID: 31449511
    [No Abstract]   [Full Text] [Related]  

  • 36. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
    Lavik AR; Zhong F; Chang MJ; Greenberg E; Choudhary Y; Smith MR; McColl KS; Pink J; Reu FJ; Matsuyama S; Distelhorst CW
    Oncotarget; 2015 Sep; 6(29):27388-402. PubMed ID: 26317541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
    Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting MCL1, Companies Aim to Unblock Apoptosis.
    Cancer Discov; 2019 May; 9(5):572. PubMed ID: 30944116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14).
    Swan D; Delaney C; Natoni A; O'Dwyer M; Krawczyk J
    Haematologica; 2020 Mar; 105(3):e141-e143. PubMed ID: 31753932
    [No Abstract]   [Full Text] [Related]  

  • 40. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.
    Saha MN; Jiang H; Yang Y; Reece D; Chang H
    Mol Cancer Ther; 2013 Nov; 12(11):2331-41. PubMed ID: 24030633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.